×
About 163 results

ALLMedicine™ Dysfibrinogenemia Center

Research & Reviews  62 results

Thrombin Time
http://emedicine.medscape.com/article/2086278-overview

May 5th, 2022 - Reference Range Thrombin time is a screening coagulation test designed to assess fibrin formation from fibrinogen in plasma. The reference range for the thrombin time is usually less than 20 seconds (ie, 15-19 seconds), but this depends on the tes...

Dysfibrinogenemia
https://emedicine.medscape.com/article/199723-overview

Apr 28th, 2022 - Practice Essentials Dysfibrinogenemia is a rare coagulation disorder resulting from an abnormal or decreaased level of fibrinogen, which is a 340 kDa glycoprotein produced in the liver, necessary to form blood clots and control bleeding. Dysfibrin...

Mutations Accounting for Congenital Fibrinogen Disorders: An Update.
https://doi.org/10.1055/s-0041-1742170
Seminars in Thrombosis and Hemostasis; Richard M, Celeny D et. al.

Jan 25th, 2022 - Fibrinogen is a complex protein that plays a key role in the blood clotting process. It is a hexamer composed of two copies of three distinct chains: Aα, Bβ, and γ encoded by three genes, FGA, FGB, and FGG, clustered on the long arm of chromosome ...

Percutaneous left atrial appendage closure in patients with primary hemostasis disorder...
https://doi.org/10.1007/s10840-021-01073-0 10.1378/chest.09-1584 10.1097/FJC.0000000000000607 10.1111/hae.12445 10.1007/s11239-020-02097-5 10.1111/hae.12055 10.1016/j.hrcr.2019.01.014 10.1111/ejh.13296 10.1053/spen.2000.20075 10.1111/jth.12916 10.1111/j.1538-7836.2005.01204.x 10.1111/j.1538-7836.2009.03678.x 10.1056/NEJMcp1810479 10.1016/j.leukres.2005.03.004 10.1055/s-0039-1698756
Journal of Interventional Cardiac Electrophysiology : an ... Dognin N, Salaun E et. al.

Nov 26th, 2021 - We report our single-center experience with percutaneous left atrial appendage closure (LAAC) in patients with non-valvular atrial fibrillation (NVAF) and primary hemostasis disorders (HD). Consecutive patients with primary HD who underwent a perc...

Laboratory Methods in the Assessment of Hereditary Hemostatic Disorders.
https://doi.org/10.1016/j.hoc.2021.07.002
Hematology/oncology Clinics of North America; Cheves TA, DeMarinis S et. al.

Aug 16th, 2021 - In patients presenting with a suspect hereditary bleeding disorder a detailed bleeding history is first obtained. Testing proceeds in a tiered manner with platelet count, platelet morphology, platelet histogram, PFA-100, fibrinogen, prothrombin ti...

see more →

Drugs  2 results

Riastap - fibrinogen human injection, powder, lyophilized, for solution-CSL Behring GmbH
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903dc8d0-39da-462c-9dac-004e0c7a26cc

Jun 15th, 2021 - RIASTAP®, Fibrinogen Concentrate (Human) is a human blood coagulation factor indicated for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogen...

Fibryga - fibrinogen (human) kit-Octapharma USA Inc
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=007a93f4-d84b-1fa9-51ed-32f6140bf423

Dec 22nd, 2020 - FIBRYGA is a human fibrinogen concentrate indicated for the treatment of acute bleeding episodes in adults and children with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. FIBRYGA is not indicated for dysfibrin...

see more →

News  1 results

Fast Five Quiz: Test Your Knowledge of Venous Thromboembolism
https://reference.medscape.com/viewarticle/902400_2

Dec 3rd, 2018 - Nephrotic syndrome is one of several disease states that increase a patient's risk of developing VTE. VTE associated with nephrotic syndrome appears to be due to a hypercoagulable state resulting from urinary loss of anticoagulant proteins, togeth...

see more →